A 96‐Week, Double‐Blind, Randomized, Controlled Trial Comparing Bexagliflozin to Glimepiride as an Adjunct to Metformin for the Treatment of Type 2 Diabetes in Adults

Yuan‐Di Halvorsen,John Paul Lock,Juan P. Frias,Francisco José Tinahones, Dominik Dahl,Annie L Conery,Mason W Freeman

Diabetes, Obesity and Metabolism（2022）

引用 5|浏览9

暂无评分

摘要

Bexagliflozin was noninferior to glimepiride in lowering HbA1c, was superior to glimepiride for decreases in body mass and SBP, and was associated with significantly fewer hypoglycaemic events than glimepiride. A favourable effect on eGFR was observed.

查看译文

关键词

FPG,HbA1c,SBP,SGLT2,bexagliflozin,body mass,glimepiride

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要